Cancer BiologybioRxivPreprint
The MYC axis in advanced prostate cancer is impacted through concurrent targeting of ERβ and AR using a novel ERβ-selective ligand alongside Enzalutamide
J. S. Gray, S. A. Wani, S. Hussain…·M. J. Campbell
This study shows that combining a novel ERβ ligand with Enzalutamide reduces MYC signaling and growth in advanced prostate cancer.
DOI 10.1101/2023.11.15.567282